Firebrick Pharma Limited (FRE) Stock Statistics & Valuation Metrics

Firebrick Pharma Limited has a market cap or net worth of AU$9.19M. The enterprise value is AU$11.46.

Firebrick Pharma Limited has 287,198,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Firebrick Pharma Limited’s return on equity (ROE) is -1.69 and return on invested capital (ROIC) is -168.60%.

The current PE Ratio of Firebrick Pharma Limited is ―. Firebrick Pharma Limited’s PEG ratio is -0.06.

In the last 12 months, Firebrick Pharma Limited had revenue of 293.42K and earned -2.63M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -2.24M and capital expenditures -16.50K, giving a free cash flow of -2.25M billion.

Firebrick Pharma Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Firebrick Pharma Limited upcoming earnings date is Mar 3, 2027, TBA (Confirmed).

Firebrick Pharma Limited as a current ratio of 5.47, with Debt / Equity ratio of 0.00%

In the past 12 months, Firebrick Pharma Limited has paid -222.09K in taxes.

Firebrick Pharma Limited EV to EBITDA ratio is -4.22, with an EV/FCF ratio of -6.47.

Firebrick Pharma Limited has AU$1.44M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$1.44M billion.

Gross margin is -68.29%, with operating margin of -976.65%, and net profit margin of -897.83%.

The average price target for Firebrick Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―